Evidence map›Paper›PMID 32752259›Full record

ArticleInternational journal of molecular sciences2020

Martina Pirro, Yassene Mohammed, Sandra J van Vliet, Yoann Rombouts, Agnese Sciacca, Arnoud H de Ru, George M C Janssen, Rayman T N Tjokrodirijo, Manfred Wuhrer, Peter A van Veelen and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Glycoproteins Presenting Galactose andInternational journal of molecular sciences · 2021
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Martina PirroCenter for Proteomics and Metabolomics, Leiden University Medical Center, 2333ZC Leiden, The Netherlands.ORCID 0000-0001-9562-2395
Yassene MohammedCenter for Proteomics and Metabolomics, Leiden University Medical Center, 2333ZC Leiden, The Netherlands.
Sandra J van VlietDepartment of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam UMC, 1105AZ Amsterdam, The Netherlands.
Yoann RomboutsInstitut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, 31077 Toulouse, France.ORCID 0000-0003-4482-2199
Agnese SciaccaCenter for Proteomics and Metabolomics, Leiden University Medical Center, 2333ZC Leiden, The Netherlands.
Arnoud H de RuCenter for Proteomics and Metabolomics, Leiden University Medical Center, 2333ZC Leiden, The Netherlands.
George M C JanssenCenter for Proteomics and Metabolomics, Leiden University Medical Center, 2333ZC Leiden, The Netherlands.
Rayman T N TjokrodirijoCenter for Proteomics and Metabolomics, Leiden University Medical Center, 2333ZC Leiden, The Netherlands.
Manfred WuhrerCenter for Proteomics and Metabolomics, Leiden University Medical Center, 2333ZC Leiden, The Netherlands.ORCID 0000-0002-0814-4995
Peter A van VeelenCenter for Proteomics and Metabolomics, Leiden University Medical Center, 2333ZC Leiden, The Netherlands.
Paul J HensbergenCenter for Proteomics and Metabolomics, Leiden University Medical Center, 2333ZC Leiden, The Netherlands.ORCID 0000-0002-3193-5445
Leiden University Medical Center · NLAmsterdam University Medical Centers · NLCentre National de la Recherche Scientifique · FR

Funding

Horizon 2020 676421ZonMw 91116004
6 · The paper itself

Abstract

Colorectal cancer (CRC) is the second-leading cause of cancer death worldwide due in part to a high proportion of patients diagnosed at advanced stages of the disease. For this reason, many efforts have been made towards new approaches for early detection and prognosis. Cancer-associated aberrant glycosylation, especially the Tn and STn antigens, can be detected using the macrophage galactose-type C-type lectin (MGL/CLEC10A/CD301), which has been shown to be a promising tool for CRC prognosis. We had recently identified the major MGL-binding glycoproteins in two high-MGL-binding CRC cells lines, HCT116 and HT29. However, we failed to detect the presence of

Indexed as

Blotting, WesternCDX2 Transcription FactorChromatography, High Pressure LiquidColorectal NeoplasmsGlycoproteinsGlycosylationHCT116 CellsHT29 CellsHumansLectins, C-TypePolysaccharidesProtein BindingProteomeProteomicsTandem Mass SpectrometryCDX2 Transcription FactorCLEC10A protein, humanGlycoproteinsLectins, C-TypeMGL lectin, humanPolysaccharidesProteomeColorectal cancerC-type lectinGlycoproteomicsLacdiNAcTMT labelingTn antigen

Identifiers

PMID32752259
PMCPMC7432225
OpenAlexW3046383751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.